Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir

Shares of Gilead Sciences, Inc. GILD were down 5.8% after it reportedly asked the FDA to rescind the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.